2016_151860-Disclosures_and_Contributions

Haematologica HAEMATOL/2016/151860 Version 2
Haematologica
HAEMATOL/2016/151860
Version 2
Autotransplant with and without induction chemotherapy in older
multiple myeloma patients: long-term outcome of a randomized trial
Christian Straka, Peter Liebisch, Hans Salwender, Burkhard
Hennemann, Bernd Metzner, Stefan Knop, Sigrid Adler-Reichel,
Christian Gerecke, Hannes Wandt, Martin Bentz, Tim Hendrik
Bruemmendorf, Marcus Hentrich, Michael Pfreundschuh,
Hans-Heinrich Wolf, Orhan Sezer, Ralf Bargou, Wolfram Jung, Lorenz
Trümper, Bernd Hertenstein, Else Heidemann, Helga Bernhard, Nicola
Lang, Norbert Frickhofen, Holger Hebart, Ralf Schmidmaier, Andreas
Sandermann, Tobias Dechow, Albrecht Reichle, Brigitte Schnabel,
Kerstin Schäfer-Eckart, Christian Langer, Martin Gramatzki, Axel Hinke,
Bertold Emmerich, and Hermann Einsele
Collaborative Groups: DSMM (Deutsche Studiengruppe Multiples
Myelom)
Disclosures: Conflict-of-interest disclosure: T.B. has received documentation fee within the
study. R.B. has received personal fee from Amgen, Novartis and Astra Zeneca. H. S. has
received grant support from Chugai. R.S. has received personal fees from Roche and
Amgen, non-financial support from Celgene, Amgen, Alexion and Lilly. C.L. has received
grant support from ElseKröner-Fresenius Stiftung. H.E. has received grant support from
Celgene, Janssen and Novartis. The remaining authors declare no competing financial
interests.
Contributions: Contributions: C.S. was the principal investigator, and was involved in the
original idea and design of the study, writing the protocol, analyzing and interpreting the
data, and writing the manuscript. A.H. planned and performed the statistical analyses. P.L.
and C.L. performed the cytogenetic analyses. All authors were involved in patient
recruitment and reviewed and approved the paper.